Laboratory Testing for Opioids

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Clinical Biochemist, Alberta Precision Laboratories, Clinical Associate Professor, Cumming School of Medicine, University of Calgary
    Biography

      Jessica Boyd is a Clinical Biochemist at Alberta Precision Laboratories (Calgary) and a Clinical Associate Professor in the Cumming School of Medicine at the University of Calgary. Dr. Boyd completed her Ph.D. in Analytical and Environmental Toxicology at the University of Alberta in 2012 and Clinical Biochemistry Fellowship training at Calgary Laboratory Services/University of Calgary in 2015. She is currently the co-director of the Analytical Toxicology Laboratory at APL-Calgary.  Her areas of interest include urine drugs of abuse testing, therapeutic drug monitoring and endocrine markers.


    Abstract

    The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screening. Setting up and selecting tests for urine drug screening can be challenging even for experienced laboratories. Many labs rely on a screen and confirm approach, combining immunoassay screens with definitive mass spectrometry analysis. However, selection of appropriate tests and cutoffs depends on the patient population and type of service. In addition, interpretation of this testing can be very challenging as laboratory staff and clinicians require knowledge of drug metabolism, drug windows of detection and analytical detection and performance. In this presentation, Dr. Boyd will give an overview of options for opioid testing including immunoassay and MS testing, and the interpretive challenges of each. She will also show how her lab has changed their urine drug screen workflow to address the challenges of the opioid epidemic.

    Learning Objectives:

    1. Discuss the impact of the opioid crisis on the clinical laboratory

    2. Discuss important factors in setting up a urine drug screening program

    3. Compare available techniques for urine drug screening for opioids and challenges in interpretation


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources